| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/19/2023 | 240.56% | JP Morgan | $31 → $11 | Maintains | Overweight |
| 08/11/2023 | 240.56% | Credit Suisse | → $11 | Reiterates | Neutral → Neutral |
| 05/12/2023 | 240.56% | Credit Suisse | → $11 | Reiterates | Neutral → Neutral |
| 03/17/2023 | 240.56% | Credit Suisse | $12 → $11 | Maintains | Neutral |
| 01/03/2023 | 488.24% | Wells Fargo | → $19 | Upgrades | Equal-Weight → Overweight |
| 10/13/2022 | 581.11% | UBS | → $22 | Initiates Coverage On | → Buy |
| 08/15/2022 | 519.2% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 05/12/2022 | 550.15% | Piper Sandler | $40 → $21 | Maintains | Overweight |
| 04/28/2022 | 488.24% | Credit Suisse | → $19 | Initiates Coverage On | → Neutral |
| 02/10/2022 | 488.24% | Wells Fargo | → $19 | Initiates Coverage On | → Equal-Weight |
| 10/14/2021 | 519.2% | SVB Leerink | → $20 | Initiates Coverage On | → Market Perform |
| 07/19/2021 | 828.79% | Guggenheim | → $30 | Initiates Coverage On | → Buy |
| 07/19/2021 | 1138.39% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
| 07/19/2021 | 1076.47% | JP Morgan | → $38 | Initiates Coverage On | → Overweight |
What is the target price for Monte Rosa Therapeutics (GLUE)?
There is no price target for Monte Rosa Therapeutics
What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?
There is no analyst for Monte Rosa Therapeutics
When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?
There is no next analyst rating for Monte Rosa Therapeutics
Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?
There is no next analyst rating for Monte Rosa Therapeutics